J. Kellogg Parsons, MD, MHS, FACS, presented “Men with High-Risk Prostate Cancer Should Not Undergo Neoadjuvant Therapy Prior to Surgery” during the Perspectives in Urology: Point Counterpoint 2020 virtual conference in November 2020.
How to cite: Parsons, J. Kellogg. “Men with High-Risk Prostate Cancer Should Not Undergo Neoadjuvant Therapy Prior to Surgery” November 2020. Accessed Dec 2024. https://dev.grandroundsinurology.com/men-with-high-risk-prostate-cancer-should-not-undergo-neoadjuvant-therapy-prior-to-surgery/
Men with High-Risk Prostate Cancer Should Not Undergo Neoadjuvant Therapy Prior to Surgery – Summary:
J. Kellogg Parsons MD, MHS, FACS, Professor of Urology at the University of California, San Diego, explains why neoadjuvant therapy prior to surgery may not be the best option for prostate cancer patients. He reviews findings from definitive randomized clinical trials that show ADT does not improve survival, and addresses common side effects, such as cognitive impairment and loss of testosterone function. Dr. Parsons then explains AUA Clinical Guidelines published in alignment with SUO and ASTRO that strongly recommend against routine neoadjuvant therapy prior to surgery. Lastly, he gives examples of when physicians can consider the option despite such caveats.
The pro perspective of this point-counterpoint series by Robert E. Reiter, MD, was published last week on GRU.
About the Perspectives in Urology: Point Counterpoint 2020 virtual conference:
Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, as well as Program Co-Chair Dan Theodorescu, MD, PhD, this virtual conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This two-day interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking. A focus on prostate cancer was given on Wednesday, November 11th, with a focus on bladder cancer given on Thursday, November 12th.
ABOUT THE AUTHOR
J. Kellogg Parsons, MD, MHS, is a board-certified urologist who specializes in diagnosing and treating prostate cancer. He is a Professor of Urology at the University of California, San Diego. He also directs clinical trials for the Department of Urology at UC San Diego Health’s Moores Cancer Center.
Dr. Parsons is an expert in nerve-sparing robotic surgery, cryosurgery, and MRI of the prostate, and is internationally recognized for his work in prostate disease. He has repeatedly been named a top doctor in San Diego Magazine’s “Physicians of Exceptional Excellence” annual survey, performed in collaboration with the San Diego County Medical Society. He has also been recognized as one of America’s Best Doctors®.
He has published over 130 scientific research articles, edited four medical textbooks, received multiple research grants, and serves as an editor on three scientific journals. He has won numerous awards for his scientific research, lectures extensively across the US and in Europe and Asia, and serves on several national committees.
Dr. Parsons completed his residency and fellowship training at John Hopkins School of Medicine in Baltimore. He earned his medical degree from the University of Pennsylvania School of Medicine in Philadelphia and holds a Master of Health Science in Clinical Investigation degree from Johns Hopkins Bloomberg School of Public Health.
Dr. Parsons is also the award-winning author of the novels Doing Harm and Under the Knife. He is currently at work on his third book.
